Accession Therapeutics Ltd. has raised £16.6 million (US$20.3 million) in a series A round, as it prepares to take two targeted oncolytic/payload combination viruses into the clinic. At the same time, the company disclosed that the scientist who devised the tumor-only targeting mechanism is Alan Parker, professor of translational virotherapies at Cardiff University.
Astrazeneca plc is beefing up its cell therapy capabilities in immuno-oncology by acquiring Neogene Therapeutics BV for an initial outlay of $200 million. There’s up to $120 million more on the table for undisclosed milestones and what the companies called a “non-contingent consideration.” Even without the additional earnouts, the deal represents a profitable return for Neogene’s shareholders. The Amsterdam-based firm had raised $110 million in a series A round in 2020, which represented the largest A round in Europe that year. Since then, it has started to move its first program, an autologous engineered T-cell receptor (TCR) T-cell therapy directed against up to five neoantigens, toward a phase I trial in patients with solid tumors.
Swiss-American startup Opna Bio SA launched this week with a $38 million series A, a Science paper on one of its targets and a pipeline stretching from preclinical to phase II.
Catalym GmbH raised €50 million (US$51.3 million) in a series C round to expand and accelerate phase IIa development of visugromab (CTL-002), a first-in-class growth differentiation factor 15 inhibitor, across a range of solid tumor indications.
Normunity Inc. emerged from stealth by unveiling $65 million in series A funding and bold plans to tackle one of the critical issues in immuno-oncology. Normunity is based on the research of scientific founder Lieping Chen, of Yale School of Medicine, an early immuno-oncology pioneer who identified and characterized the gene encoding PD-L1 (then called B7-H1) and shortly afterward reporting additional findings that contributed to its recognition as an important target in cancer immunotherapy.
Immuno-oncology company Imugene Ltd. announced an AU$80 million (US$53.9 million) capital raise that will allow the company to add additional studies within its immuno-oncology pipeline as well as pursue potential licensing opportunities. The funds raised will allow the company to interrogate its pipeline further in other indications or combinations, Imugene CEO Leslie Chong told BioWorld. “There’s a lot we could do with our current pipeline, and now our cashflow is greatly extended.”
Immuno-oncology company Imugene Ltd. announced an AU$80 million (US$53.9 million) capital raise that will allow the company to add additional studies within its immuno-oncology pipeline as well as pursue potential licensing opportunities. The funds raised will allow the company to interrogate its pipeline further in other indications or combinations, Imugene CEO Leslie Chong told BioWorld. “There’s a lot we could do with our current pipeline, and now our cashflow is greatly extended.”
Catalym GmbH reported in an oral session at the European Society for Medical Oncology meeting in Paris that its first-in-class growth differentiation factor 15 inhibitor, visugromab, demonstrated preliminary signs of efficacy in a heavily pretreated group of cancer patients who were resistant or refractory to checkpoint inhibitors.
3T Biosciences Inc. raised $40 million in a series A funding round to take forward a platform for identifying novel T-cell receptors (TCR) and their targets, which is based on the work of scientific co-founder K. Christopher Garcia of Stanford University.
London-based Invox Pharma Ltd. has announced plans to acquire F-star Therapeutics Inc. for $161 million to build up the presence of its parent company, Sino Biopharm Ltd., outside of China.
